Wird geladen...
Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update
Malignancy after solid organ transplantation remains a major cause of posttransplant mortality. The mammalian target of rapamycin (mTOR) inhibitor class of immunosuppressants exerts various antioncogenic effects, and the mTOR inhibitor everolimus is licensed for the treatment of several solid cancer...
Gespeichert in:
| Veröffentlicht in: | J Transplant |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Hindawi Publishing Corporation
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5078653/ https://ncbi.nlm.nih.gov/pubmed/27807479 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/4369574 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|